{"url_path":"/sec/cik-0001697884/10-k/2026/item-10","section_key":"item-10","section_title":"Item 10 Directors, Executive Officers, and Corporate Governance.**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1697884/0001640334-26-001082-index.html","accession_number":"0001640334-26-001082","cik":"0001697884","ticker":null,"issuer_name":"VITASPRING BIOMEDICAL CO. LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1697884/0001640334-26-001082-index.html","primary_entity_key":"0001697884","primary_entity_name":"VITASPRING BIOMEDICAL CO. LTD."},"word_count":1158,"has_tables":true,"body_markdown":"**Item 10. Directors, Executive Officers, and Corporate Governance.**\n\n \n\nThe board of directors elects our executive officers annually. A majority vote of the directors who are in office is required to fill vacancies. Each director is elected for the term of one year, and until his or her successor is elected and qualified, or until his earlier resignation or removal. As of January 31, 2026, we had only one director. The name, address, age and position of our officers and sole director is as follows:\n\n \n\n**Name and Address of Executive**\n\n**Officer and/or Director**\n\n**Age**\n\n**Position**\n\n**Served Since**\n\nSsu-Chuan Lai, Ph.D.\n\n5225 Canyon Crest Dr., Ste 71-825\n\nRiverside CA 92507\n\n41\n\nChairperson, Chief Executive Officer, President, CFO, Treasurer, and Secretary\n\nAugust 7, 2025\n\n \n\n**Ssu-Chuan Lai, Ph.D.**has served as our sole director, chief executive officer, president, chief financial officer and treasurer, and secretary since August 7, 2025.\n\n \n\nDr. Lai holds a Ph.D. in Medical Science from Taipei Medical University, as well as M.S. and B.S. degrees in Physical Therapy from China Medical University and Tzu Chi University, respectively. She has over a decade of experience spanning biomedical research, clinical rehabilitation, and cell manufacturing operations.\n\n \n\nSince 2023, Dr. Lai has served as Vice General Manager of the Cell Manufacturing Division at Biospring Medical Co., Ltd., where she led the setup and management of a 660+ m² GTP/GMP-compliant cell manufacturing center. In this role, she oversaw cross-functional teams, ensured compliance with GTP, GMP, and ISO 17025 standards, and facilitated the transition of research projects into scalable, manufacturing-ready pipelines.\n\n \n\nPreviously, Dr. Lai held positions as Senior Engineer in the same division and as a Ph.D. Research Assistant at Taipei Medical University, focusing on stem cell and tissue engineering research for translational projects. She also has clinical experience as a licensed physical therapist in Taiwan.\n\n \n\nDr. Lai has completed full training in ISO 17025 Quality Management, Good Manufacturing Practice (GMP), and Good Tissue Practice (GTP), and is recognized for her expertise in facility setup, regulatory-compliant manufacturing, and cross-department collaboration in the biotechnology sector.\n\n \n\nThe board of directors elects our executive officers annually. A majority vote of directors who are in office is required to fill vacancies. Each director is elected for the term of one year, and until his or her successor is elected and qualified, or until his earlier resignation or removal. From January 31, 2023, to August 7, 2025, we had only 2 directors. The name, address, age and position of our former four officers and former two directors were as follows:\n\n \n\n \n\n26\n\n*Table of Contents*\n\n \n\n**Name and Address of Executive**\n\n**Officer and/or Director**\n\n**Age**\n\n \n\n**Position**\n\n \n\n**Served Since**\n\n \n\n \n\n \n\n \n\n \n\n \n\nPao-Chi Chu\n\n10F, No. 93, Section 1\n\nXintaiwu Rd., XiZhi Dist.\n\nNew Taipei City, 221, TWN\n\n \n\n71\n\n \n\nPresident, Chairman\n\n \n\nJanuary 21, 2020\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nCheng-Hsiang Kao\n\n10F, No. 93, Section 1\n\nXintaiwu Rd., XiZhi Dist.\n\nNew Taipei City, 221, TWN\n\n \n\n71\n\n \n\nChief Executive Officer, Secretary, Director\n\n \n\nJanuary 21, 2020\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nChe-Li Lin\n\n10F, No. 93, Section 1\n\nXintaiwu Rd., XiZhi Dist.\n\nNew Taipei City, 221, TWN\n\n \n\n60\n\n \n\nChief Technical Officer\n\n \n\nJanuary 21, 2020\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nYen-Hsun Chen\n\n10F, No. 93, Section 1\n\nXintaiwu Rd., XiZhi Dist.\n\nNew Taipei City, 221, TWN\n\n \n\n40\n\n \n\nTechnical Vice President\n\n \n\nJanuary 21, 2020\n\n  \n\n**Mr. Pao-Chi Chu** served as our Chairman of the Board and President from July 2020 until his resignation on August 7, 2025. From 2006 until the present, Mr. Chu has also served as the Chairman of Mucho Biotech Co., Ltd., Chairman of Mucho Furich Co., Ltd. and Chairman of Mucho Biomedical Co., Ltd. He is a graduate of Fu Jen Catholic University, Taipei, Taiwan.\n\n \n\n**Mr. Cheng-Hsiang Kao** served as our Chief Executive Officer, Secretary, and a director from July 2020 until his resignation on August 7, 2025. From 2016 until 2020, Mr. Kao has been the CEO of, Mucho Furich Co., Ltd. From 2004 until 2016, he was a CEO of Mucho Biotech Co., Ltd. He is a graduate of National Chengchi University, Department of Diplomacy.\n\n \n\n**Mr. Che-Li Lin**served as our Chief Technical Officer from January 21, 2020, until his resignation on August 7, 2025. From 2017 until 2020, Mr. Lin served as the Tech. VP of Mucho Biotech Co., Ltd. From 2010 until 2016, he was a Project manager of Da Jer Biotech Co., Ltd. Mr. Lin is a graduate of National Taiwan University, MS, Institute of Biochemistry.\n\n  \n\n**Mr. Yen-Hsun Chen** served as our Technical Vice President from January 21, 2020, until his resignation on August 7, 2025. From 2017 to 2020, Mr. Chen has been the Tech. VP of Mucho Biotech Co., Ltd. From 2010 until 2016, he was a Supervisor of Taiwan Cordyceps Association. Mr. Chen is a graduate of National Taiwan University, MS, Institute of Fisheries Science.\n\n \n\n**Corporate Governance**\n\n \n\nWe did not maintain standing audit, compensation, or nominating committees during the period. The Board performed the functions of such committees.\n\n \n\nWe were in the development stage since 2023 and operated with limited personnel and resources. As we expand our operations, we intend to implement appropriate corporate governance practices consistent with the requirements applicable to smaller reporting companies.\n\n \n\n \n\n27\n\n*Table of Contents*\n\n \n\n**Principal Executive Offices**\n\n \n\nDuring fiscal 2024 and 2023, we maintained a branch office located at 1F., No. 95, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City, Taiwan, where the former management team operated. From August 2021 to July 2024, we maintained our principal executive offices at 400 Spectrum Center Dr., Suite 1620, Irvine, CA 92618. In May 2025, we relocated our executive offices to 5225 Canyon Crest Dr., Suite 71-825, Riverside, CA 92507. The Riverside location serves as our current executive office as of the date of this report.\n\n \n\n**Subsequent Changes in Management**\n\n \n\nEffective August 7, 2025, Ms. Ssu-Chuan Lai was appointed as our Chief Executive Officer, President, Chief Financial Officer, Secretary, Treasurer, and sole Director. Messrs. Kao, Chu, Lin, and Chen resigned from all officer and director positions effective August 7, 2025. Ms. Ssu-Chuan Lai currently serves as our sole executive officer and director as of the date of this filing.\n\n \n\n**Delinquent Section 16(a) Reports**\n\n \n\nOur common stock is not registered pursuant to Section 12 of the Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, our officers, director and principal stockholders are not subject to the beneficial ownership reporting requirements of Section 16(a) of the Exchange Act.\n\n \n\n**Code of Business Conduct**\n\n \n\nWe have not adopted a Code of Business Conduct within the meaning of Item 406(b) of Regulation S-K. We intend to adopt one in Q2 of 2026.\n\n \n\n**Board Committees**\n\n \n\nAs of the date of this filing, since we have only one director, we do not have any standing committees of our Board of Directors, such as an audit committee, compensation committee, or nominating and corporate governance committee. The functions customarily attributable to such committees are currently performed by our sole director.\n\n \n\nWe intend to evaluate the formation of appropriate Board committees as our operations grow and as required to comply with applicable regulatory or exchange listing requirements.\n\n \n\n \n\n28\n\n*Table of Contents*"}